1.	Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 3160A4-3000, B1871008, NCT00574873
2.	Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 3160A4-200, B1871006, 3160A4-200-WW, NCT00261846
3.	Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 3160A6-2208, B1871011, NCT00959946
4.	Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 3160A2-201, B1871014, NCT00319254
5.	Study Evaluating SKI-606 (Bosutinib) In Advanced Malignant Solid Tumors Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 3160A1-100, B1871012, NCT00195260
6.	Study Evaluating The Pharmacokinetics (PK) And Safety Of Bosutinib In Subjects With Liver Disease And In Healthy Subjects Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 to 65 Sponsor: Other Protocol IDs: 3160A4-1111, NCT00759837
7.	Bioequivalence And Food Effect Study Of Bosutinib In Healthy Subjects Phase: Phase I Type: Biomarker/Laboratory analysis Status: Completed Age: 21 to 55 Sponsor: Pharmaceutical / Industry Protocol IDs: B1871035, NCT01374139